In the article “High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil”, published in Braz J Infect Dis. 2013 Feb;17(1):41-7, please consider the following corrections:
Page 43, Table 1, line 18, “Previous use of NRTI, NNRTI and PIs: 87 (95)” should read as “Previous use of NRTI, NNRTI and PIs: 92 (100%)”.
Page 43, Results section, lines 28-31, “Tenofovir was the most frequent NRTI used (n=83, 90.2%) and its genotyping evaluation were: sensitive: 16 (17.4%), intermediate resistance: 8 (8.7%), and resistance: 68 (73.9%).” should read as “All patients received lamivudine and their genotyping evaluation were resistant in all cases. Tenofovir was the second most frequent NRTI used (n=83, 90.2%) and its genotyping evaluation were: sensitive:14 (16.9%), intermediate resistance: 7 (8.4%), and resistance: 62 (74.7%).”
DOI of the original article: http://dx.doi.org/10.1016/j.bjid.2012.08.022
